HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG
Recruiting now · Not applicable
Conditions studied: Multiple Cancers, Multiple Indications Cancer, Feasibility Studies
In brief
Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.
Key facts
- Study ID
- NCT07295171
- Run by
- British Columbia Cancer Agency
- People needed
- 27
- Starts
- 2026-02-18
- Expected to finish
- 2027-02-18
- Last updated by the study team
- 2026-03-31
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥19 years
- Participants who have received a standard of care [18F]FDG PET/CT and are willing to undergo a study specific oral [18F]FDG PET/CT within 2 weeks.
You may not qualify if…
- Participant Inclusion Criteria
- Age ≥19 years
- Participants who have received a standard of care [18F]FDG PET/CT and are willing to undergo a study specific oral [18F]FDG PET/CT within 2 weeks.
- Participant Exclusion Criteria
- Pregnant or breast-feeding
- Medically unstable (e.g., acute illness, unstable vital signs)
- Urinary incontinence/catheter.
- Immobile, frail or vulnerable patients who cannot leave the department and would require an uptake room in any case.
- Patients whose fasting blood sugar at the SOC PET was >11.0 mmol/l
- Unable to swallow.
- Patients with nasogastric tubes, percutaneous gastrostomy or other non-anatomical routes for nutrition.
- Unable to lie flat for 1h (subset of participants - first 5 participants only).
- Claustrophobia requiring medication.
- Undergoing active treatment or assessment of an upper digestive tract tumor (stomach/esophagus)
- Unable to provide written consent
- Patients receiving biguanide anti-hyperglycemic agents (e.g. Metformin).
- Insulin dependent diabetics.
Where it is running
- BC Cancer Vancouver — Vancouver, British Columbia, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.